COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT04333368


Column Value
Trial registration number NCT04333368
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

First author
Last imported at : Dec. 7, 2020, 12:31 a.m.
Source : ClinicalTrials.gov

Antoine MONSEL

Contact
Last imported at : Dec. 7, 2020, 12:31 a.m.
Source : ClinicalTrials.gov

antoine.monsel@aphp.fr

Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2020-04-03

Recruitment status
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Blind label

Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov

multi-center

Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Treatment

Inclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

inclusion criteria: - male or female patient, age > 18 years, - laboratory (rt-pcr)-confirmed infection with sars-cov2 - diagnosis of ards according to the berlin definition of ards - under invasive, non-invasive ventilation or high-flow nasal oxygen therapy (peep ≥ 5 cmh2o) - onset of ards <96 hours - patient with french social security system - provision of a written informed consent by the designated substitute decision maker, if present. in the event of absence, the patient can be included by investigator's decision alone.

Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

- previous history of ards in the last month - chronic respiratory diseases requiring long-term oxygen therapy and/or long-term respiratory assistance - allogeneic bone marrow transplantation - active cancer - liver cirrhosis with basal child and pugh of c - pulmonary fibrosis - patient with end-of-life decision - patient not expected to survive for 24 hours - patient who received an organ transplant - woman known to be pregnant or lactating - patient already enrolled in another interventional pharmacotherapy protocol on covid-19 - patient has burns to ≥15% of their total body surface area - patient is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support - patient under tutelage

Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2

Funding
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Assistance Publique - Hôpitaux de Paris

Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

18

Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Countries
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

France

Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Critical disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

8: Critical disease at enrollment

Total sample size
Last imported at : Dec. 7, 2020, 12:31 a.m.
Source : ClinicalTrials.gov

47

primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group

Notes
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov

Phase 1/Phase 2

Arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

[{"arm_notes": "", "treatment_id": 1335, "treatment_name": "Umbilical cord wharton\u2019s jelly derived mesenchymal stem cells", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]